Efficacy and safety of donanemab in the European eligible population: TRAILBLAZER-ALZ 2 post-hoc analyses. - Jessen F; Dell'Agnello G; Zimmer JA; Sapin C; Dichter S; Doty E; Epelbaum S; Evans CD; Hauck PM; Khanna R; Brooks DA; Sims JR; et al. (The journal of prevention of Alzheimer's disease, 2026)